These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 7557947)

  • 1. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
    Buø L; Meling GI; Karlsrud TS; Johansen HT; Aasen AO
    Hum Pathol; 1995 Oct; 26(10):1133-8. PubMed ID: 7557947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen Activation System in Rectal Adenocarcinoma.
    Razik E; Kobierzycki C; Grzegrzolka J; Podhorska-Okolow M; Drag-Zalesinska M; Zabel M; Dziegiel P
    Anticancer Res; 2015 Nov; 35(11):6009-15. PubMed ID: 26504024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
    Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
    Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activator system in oral squamous cell carcinoma.
    Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
    Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.
    Plebani M; Herszènyi L; Carraro P; De Paoli M; Roveroni G; Cardin R; Tulassay Z; Naccarato R; Farinati F
    Clin Exp Metastasis; 1997 Jul; 15(4):418-25. PubMed ID: 9219730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression.
    Baker EA; Bergin FG; Leaper DJ
    Mol Pathol; 2000 Dec; 53(6):307-12. PubMed ID: 11193049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer.
    Ganesh S; Sier CF; Heerding MM; van Krieken JH; Griffioen G; Welvaart K; van de Velde CJ; Verheijen JH; Lamers CB; Verspaget HW
    Br J Cancer; 1997; 75(12):1793-801. PubMed ID: 9192984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
    Zheng Q; Tang ZY; Xue Q; Shi DR; Song HY; Tang HB
    J Cancer Res Clin Oncol; 2000 Nov; 126(11):641-6. PubMed ID: 11079728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas.
    Papadopoulou S; Scorilas A; Yotis J; Arnogianaki N; Plataniotis G; Agnanti N; Talieri M
    Tumour Biol; 2002; 23(3):170-8. PubMed ID: 12218297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
    Fuessel S; Erdmann K; Taubert H; Lohse-Fischer A; Zastrow S; Meinhardt M; Bluemke K; Hofbauer L; Fornara P; Wullich B; Baretton G; Magdolen V; Wirth MP; Kotzsch M
    BMC Cancer; 2014 Dec; 14():974. PubMed ID: 25519168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis.
    Nozaki S; Endo Y; Kawashiri S; Nakagawa K; Yamamoto E; Yonemura Y; Sasaki T
    Oral Oncol; 1998 Jan; 34(1):58-62. PubMed ID: 9659521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serine proteinase activation in esophageal cancer.
    Tang WH; Friess H; Kekis PB; Martignoni ME; Fukuda A; Roggo A; Zimmerman A; Büchler MW
    Anticancer Res; 2001; 21(4A):2249-58. PubMed ID: 11724279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
    Chambers SK; Gertz RE; Ivins CM; Kacinski BM
    Cancer; 1995 Apr; 75(7):1627-33. PubMed ID: 8826920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma.
    Nakanishi K; Kawai T; Torikata C; Aurues T; Ikeda T
    Cancer; 1998 Feb; 82(4):724-32. PubMed ID: 9477106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.
    Kaneko T; Konno H; Baba M; Tanaka T; Nakamura S
    Cancer Sci; 2003 Jan; 94(1):43-9. PubMed ID: 12708473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S; Vrhovec I; Svetic B; Cufer T
    Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
    Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer.
    Borgfeldt C; Bendahl PO; Gustavsson B; Långström E; Fernö M; Willén R; Grenman S; Casslén B
    Int J Cancer; 2003 Nov; 107(4):658-65. PubMed ID: 14520707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
    Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
    Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.